OBJECTIVE: To assess the feasibility and safety of remifentanil-based sedation during noninvasive ventilation (NIV) in patients with NIV failure. DESIGN AND SETTING: Prospective clinical investigation in a 16-bed intensive care unit of a university hospital in France. PATIENTS: Thirteen patients in NIV failure due to discomfort and/or refusal to continue this ventilatory support: 10 with acute respiratory failure and 3 with acute hypercapnic respiratory failure. INTERVENTION: Patients were administered methylene blue and were sedated (Ramsay scale 2-3) by a continuous perfusion of remifentanil during NIV. Cardiorespiratory and ventilatory parameters, blood gas analysis, and adverse events were prospectively recorded. MEASUREMENTS AND RESULTS: The 13 patients received a total of 125 NIV sessions, totaling 1200 h, of NIV under remifentanil-based sedation (mean remifentanil dose 0.1+/-0.03 microg/kg per minute). Three patients also required propofol. PaO2/FIO2 ratio increased from 134+/-69 to 187+/-43 mmHg after 1 h. In patients with acute respiratory failure respiratory rate decreased from 34+/-12 per minute before remifentanil to 25+/-4 per minute after 1h. In the three patients with acute hypercapnic respiratory failure PaCO2 decreased from 69+/-7 to 42+/-5 mmHg. Four patients required endotracheal intubation without aspiration pneumonia. Twelve of the 13 patients left the ICU. CONCLUSION: This pilot study shows that remifentanil-based sedation is safe and effective in the treatment of NIV failure due to low tolerance.
OBJECTIVE: To assess the feasibility and safety of remifentanil-based sedation during noninvasive ventilation (NIV) in patients with NIV failure. DESIGN AND SETTING: Prospective clinical investigation in a 16-bed intensive care unit of a university hospital in France. PATIENTS: Thirteen patients in NIV failure due to discomfort and/or refusal to continue this ventilatory support: 10 with acute respiratory failure and 3 with acute hypercapnic respiratory failure. INTERVENTION: Patients were administered methylene blue and were sedated (Ramsay scale 2-3) by a continuous perfusion of remifentanil during NIV. Cardiorespiratory and ventilatory parameters, blood gas analysis, and adverse events were prospectively recorded. MEASUREMENTS AND RESULTS: The 13 patients received a total of 125 NIV sessions, totaling 1200 h, of NIV under remifentanil-based sedation (mean remifentanil dose 0.1+/-0.03 microg/kg per minute). Three patients also required propofol. PaO2/FIO2 ratio increased from 134+/-69 to 187+/-43 mmHg after 1 h. In patients with acute respiratory failure respiratory rate decreased from 34+/-12 per minute before remifentanil to 25+/-4 per minute after 1h. In the three patients with acute hypercapnic respiratory failurePaCO2 decreased from 69+/-7 to 42+/-5 mmHg. Four patients required endotracheal intubation without aspiration pneumonia. Twelve of the 13 patients left the ICU. CONCLUSION: This pilot study shows that remifentanil-based sedation is safe and effective in the treatment of NIV failure due to low tolerance.
Authors: J F Hoke; D Shlugman; M Dershwitz; P Michałowski; S Malthouse-Dufore; P M Connors; D Martel; C E Rosow; K T Muir; N Rubin; P S Glass Journal: Anesthesiology Date: 1997-09 Impact factor: 7.892
Authors: Giorgio Conti; Roberta Costa; Aristide Pellegrini; Andrea Craba; Franco Cavaliere Journal: Curr Drug Targets Date: 2005-11 Impact factor: 3.465
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2008-01-31 Impact factor: 17.440
Authors: Alfonso Muriel; Oscar Peñuelas; Fernando Frutos-Vivar; Alejandro C Arroliga; Victor Abraira; Arnaud W Thille; Laurent Brochard; Nicolás Nin; Andrew R Davies; Pravin Amin; Bin Du; Konstantinos Raymondos; Fernando Rios; Damian A Violi; Salvatore M Maggiore; Marco Antonio Soares; Marco González; Fekri Abroug; Hans-Henrik Bülow; Javier Hurtado; Michael A Kuiper; Rui P Moreno; Amine Ali Zeggwagh; Asisclo J Villagómez; Manuel Jibaja; Luis Soto; Gabriel D'Empaire; Dimitrios Matamis; Younsuck Koh; Antonio Anzueto; Niall D Ferguson; Andrés Esteban Journal: Intensive Care Med Date: 2015-05-14 Impact factor: 17.440
Authors: Monica Rocco; Giorgio Conti; Elisa Alessandri; Andrea Morelli; Gustavo Spadetta; Amalia Laderchi; Carmela Di Santo; Samanta Francavilla; Paolo Pietropaoli Journal: Intensive Care Med Date: 2010-09-17 Impact factor: 17.440